Pharmaceuticals 2011, 4(12), 1518-1534; doi:10.3390/ph4121518
Article

Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments

Received: 31 August 2011; in revised form: 16 November 2011 / Accepted: 18 November 2011 / Published: 25 November 2011
(This article belongs to the Special Issue Antivirals)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in serious cases influenza A leads to pneumonia, which is particularly fatal in patients with cardiopulmonary diseases, obesity, young children and the elderly. In the present study, we show a protective effect of the low-molecular weight compound Ingavirin (6-[2-(1H-imidazol-4-yl)ethylamino]-5-oxohexanoic acid) against influenza A (H1N1) virus, human parainfluenza virus and human adenovirus infections in animals. Mortality, weight loss, infectious titer of the virus in tissues and tissue morphology were monitored in the experimental groups of animals. The protective action of Ingavirin was observed as a reduction of infectious titer of the virus in the lung tissue, prolongation of the life of the infected animals, normalization of weight dynamics throughout the course of the disease, lowering of mortality of treated animals compared to a placebo control and normalization of tissue structure. In case of influenza virus infection, the protective activity of Ingavirin was similar to that of the reference compound Tamiflu. Based on the results obtained, Ingavirin should be considered as an important part of anti-viral prophylaxis and therapy.
Keywords: influenza; parainfluenza virus; adenovirus; pandemic; Ingavirin; antiviral; animal model
PDF Full-text Download PDF Full-Text [3893 KB, uploaded 25 November 2011 16:20 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Zarubaev, V.V.; Garshinina, A.V.; Kalinina, N.A.; Shtro, A.A.; Belyaevskaya, S.V.; Slita, A.V.; Nebolsin, V.E.; Kiselev, O.I. Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments. Pharmaceuticals 2011, 4, 1518-1534.

AMA Style

Zarubaev VV, Garshinina AV, Kalinina NA, Shtro AA, Belyaevskaya SV, Slita AV, Nebolsin VE, Kiselev OI. Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments. Pharmaceuticals. 2011; 4(12):1518-1534.

Chicago/Turabian Style

Zarubaev, Vladimir V.; Garshinina, Angelica V.; Kalinina, Nelly A.; Shtro, Anna A.; Belyaevskaya, Svetlana V.; Slita, Alexander V.; Nebolsin, Vladimir E.; Kiselev, Oleg I. 2011. "Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxo-hexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments." Pharmaceuticals 4, no. 12: 1518-1534.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert